<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03355326</url>
  </required_header>
  <id_info>
    <org_study_id>IU-IRB-1611267731</org_study_id>
    <nct_id>NCT03355326</nct_id>
  </id_info>
  <brief_title>Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis</brief_title>
  <official_title>Evaluation of Routine Administration of Glycerin Suppositories to Improve Bowel Function in Patients With Uncomplicated Gastroschisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroschisis is a congenital defect of the abdominal wall that leads to evisceration of&#xD;
      various amounts of the abdominal organs. The mainstay of therapy is restoring continuity of&#xD;
      the abdominal wall, either through primary closure or with a synthetic graft when primary&#xD;
      closure is not feasible.&#xD;
&#xD;
      It has been established that bowel function after repair of gastroschisis is impaired due to&#xD;
      the aforementioned pathological processes. Previous studies have shown that the time from&#xD;
      surgery to attaining full nutrition through enteral means is a predictor for morbidity in&#xD;
      this population. Therefore, numerous therapeutic interventions have been proposed to help&#xD;
      hasten bowel function and decrease the time to tolerance of total enteral nutrition. A&#xD;
      common, but unproven, technique is the use of glycerin suppositories to stimulate bowel&#xD;
      function. The concept of glycerin suppositories is that stimulating colonic activity through&#xD;
      the use of the suppository will stimulate small intestinal function. The underlying concept&#xD;
      is that improved bowel motility and reduced time to full enteral feeds will reduce the&#xD;
      morbidity associated with this disease. While the formation/evacuation of stools is most&#xD;
      easily monitored, the main purpose of using these suppositories is to hasten tolerance of&#xD;
      nutrition through enteral means.&#xD;
&#xD;
      While the practice of using glycerin suppositories is common in neonates, there is no&#xD;
      literature or best-practice guidelines advocating for (or against) their use. A single&#xD;
      previous prospective study utilizing glycerin suppositories in premature, low birth weight&#xD;
      neonates failed to show any benefit in improving time to tolerate full enteral feeds. At this&#xD;
      time, this is the only study investigating the use of glycerin suppositories in any neonatal&#xD;
      population, and due to the indications (i.e. premature and low birth weight infants without&#xD;
      surgical disease), the findings are not applicable to neonates with gastroschisis. To the&#xD;
      authors' knowledge, there are no previous studies or current ongoing studies examining this&#xD;
      question. Given this lack of information regarding the efficacy of glycerin suppositories,&#xD;
      there is a significant variation in practice among practicing surgeons, including timing of&#xD;
      initial administration, frequency of use, and indication to discontinue. Indeed the spectrum&#xD;
      ranges from some surgeons who never use glycerin suppositories, to some who prescribe them&#xD;
      daily for all gastroschisis patients immediately following surgery.&#xD;
&#xD;
      The purpose of this study will be to determine whether routine use of glycerin suppositories&#xD;
      improves bowel function as measured by time to full enteral feeds (primary outcome: defined&#xD;
      as enteral feed volume &gt;120mL/kg/day with appropriate weight gain (20-30g/day for two&#xD;
      consecutive days)) in neonates with uncomplicated gastroschisis after complete reduction of&#xD;
      abdominal viscera. Secondary outcomes include time to first bowel movement and&#xD;
      incidence/severity of TPN-induced cholestasis in the study groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroschisis is a congenital defect of the abdominal wall that leads to evisceration of&#xD;
      various amounts of the abdominal organs. The mainstay of therapy is restoring continuity of&#xD;
      the abdominal wall, either through primary closure or with a synthetic graft when primary&#xD;
      closure is not feasible. Closure of the abdominal cavity is confounded by prenatal loss of&#xD;
      abdominal domain coupled by resultant swelling of the abdominal viscera due to prenatal&#xD;
      exposure to amniotic fluid. Additionally, some patients with gastroschisis have other&#xD;
      concomitant abnormalities of the bowel (termed complicated gastroschisis) that require&#xD;
      additional surgical intervention.&#xD;
&#xD;
      It has been established that bowel function after repair of gastroschisis is impaired due to&#xD;
      the aforementioned pathological processes. Previous studies have shown that the time from&#xD;
      surgery to attaining full nutrition through enteral means is a predictor for morbidity in&#xD;
      this population. Therefore, numerous therapeutic interventions have been proposed to help&#xD;
      hasten bowel function and decrease the time to tolerance of total enteral nutrition. A&#xD;
      common, but unproven, technique is the use of glycerin suppositories to stimulate bowel&#xD;
      function. The concept of glycerin suppositories is that stimulating colonic activity through&#xD;
      the use of the suppository will stimulate small intestinal function. The underlying concept&#xD;
      is that improved bowel motility and reduced time to full enteral feeds will reduce the&#xD;
      morbidity associated with this disease. While the formation/evacuation of stools is most&#xD;
      easily monitored, the main purpose of using these suppositories is to hasten tolerance of&#xD;
      nutrition through enteral means.&#xD;
&#xD;
      While the practice of using glycerin suppositories is common in neonates, there is no&#xD;
      literature or best-practice guidelines advocating for (or against) their use. A single&#xD;
      previous prospective study utilizing glycerin suppositories in premature, low birth weight&#xD;
      neonates failed to show any benefit in improving time to tolerate full enteral feeds. At this&#xD;
      time, this is the only study investigating the use of glycerin suppositories in any neonatal&#xD;
      population, and due to the indications (i.e. premature and low birth weight infants without&#xD;
      surgical disease), the findings are not applicable to neonates with gastroschisis. To the&#xD;
      authors' knowledge, there are no previous studies or current ongoing studies examining this&#xD;
      question. Given this lack of information regarding the efficacy of glycerin suppositories,&#xD;
      there is a significant variation in practice among practicing surgeons, including timing of&#xD;
      initial administration, frequency of use, and indication to discontinue. Indeed the spectrum&#xD;
      ranges from some surgeons who never use glycerin suppositories, to some who prescribe them&#xD;
      daily for all gastroschisis patients immediately following surgery.&#xD;
&#xD;
      The purpose of this study will be to determine whether routine use of glycerin suppositories&#xD;
      improves bowel function as measured by time to full enteral feeds (primary outcome: defined&#xD;
      as enteral feed volume &gt;120mL/kg/day with appropriate weight gain (20-30g/day for two&#xD;
      consecutive days)) in neonates with uncomplicated gastroschisis after complete reduction of&#xD;
      abdominal viscera. Secondary outcomes include time to first bowel movement and&#xD;
      incidence/severity of TPN-induced cholestasis in the study groups.&#xD;
&#xD;
      Individuals will be followed from the time of consultation by the Pediatric General Surgery&#xD;
      service (i.e. at the time of birth) until initial discharge. Neonates undergo abdominal wall&#xD;
      closure and reach full nutrition (via either full enteral, total parenteral nutrition, or a&#xD;
      combination of both) prior to discharge.&#xD;
&#xD;
      Patients will approached by a study coordinator (Daisy Nunez or Robert Vandewalle) regarding&#xD;
      enrollment, which will occur on the day of, or prior to completion of surgical intervention.&#xD;
      Randomization into treatment/control arm, utilizing a block technique, will occur after&#xD;
      completion of surgical intervention. While the operating surgeon will technically be unaware&#xD;
      of the treatment arm of the patient at the time of surgery, neither the medical staff, study&#xD;
      participants/families, or study staff be blinded for this study.&#xD;
&#xD;
      After closure of the abdominal wall children will be cared for according to the same&#xD;
      standards used in previous/non-trial patients. The only exception is that the control-group&#xD;
      patients will not be allowed to be administered glycerin suppositories at anytime and the&#xD;
      treatment- group will receive glycerin suppositories (based upon previously established&#xD;
      institutional pharmacy dosing protocols) from the first day after abdominal wall closure&#xD;
      until they reach full enteral feeds (as defined as 120mL/kg/d with appropriate weight gain)&#xD;
      which will be determined by the surgeon of record. Initiation and advancement of enteral&#xD;
      feeds will be based upon on protocol developed for this study and agreed upon the study&#xD;
      surgeons, who are responsible for nutritional management of these patients (see attached&#xD;
      feeding protocol). Signs of feeding intolerance are outline in the attached feeding protocol.&#xD;
      Additional metrics will be recorded in the study data sheet (see attached data collection&#xD;
      sheet) this information is routinely collected as a part of normal care for patients with&#xD;
      gastroschisis but otherwise no additional interventions will be a part of the study protocol.&#xD;
      Because the most common morbidities associated with gastroschisis center on infectious&#xD;
      complications and those related to prolonged parenteral nutrition, general indicators for&#xD;
      these complications (i.e. laboratory and clinical variables) will be recorded as well.&#xD;
&#xD;
      The electronic patient chart will be reviewed on each patient each weekday of the patient's&#xD;
      hospital admission (i.e. real time data collection) and the surgery team/study coordinator&#xD;
      will contact the attending of record and/or nursing staff for clarification of any missing&#xD;
      data. Both study coordinators will review the dataset independently on a weekly basis to help&#xD;
      ensure fidelity of the database and data will be backed up on a twice a week basis.&#xD;
&#xD;
      No additional intervention, interaction, or follow up will be completed after the neonate is&#xD;
      discharged from their initial admission as part of this study.&#xD;
&#xD;
      Identified barriers to enrollment included timing of delivery/transfer to Riley Hospital for&#xD;
      proper enrollment. This will be addressed by the investigators reviewing the general surgery&#xD;
      census list on a daily basis to identify patients early and provide time for patient/family&#xD;
      consideration for enrollment. Additional enrollment barriers include language barriers which&#xD;
      will be addressed with interpreter requests when available and translator phone when live&#xD;
      interpreters are not available and/or not feasible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to sufficiently recruit candidates&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Full Enteral Feeds</measure>
    <time_frame>2 months</time_frame>
    <description>time from study start time to goal full feeds by enteral route (per oral (PO), orogastric (OG), gastrostomy tube (gtube)).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Bowel Movement</measure>
    <time_frame>1 month</time_frame>
    <description>time from study start time after closure to first bowel movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>~3 months</time_frame>
    <description>time from admission (birth) to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Total Parenteral Nutrition (TPN)</measure>
    <time_frame>2 months</time_frame>
    <description>total time that patient required Total Parenteral Nutrition (TPN) feeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sequela of Long Term Total Parenteral Nutrition (TPN) Administration</measure>
    <time_frame>~3 months</time_frame>
    <description>Any complications related to TPN administration, including TPN-induced cholestasis and hyperbilirubinemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infectious Complications</measure>
    <time_frame>~3 months</time_frame>
    <description>Any complications related to infections during the admission after start of study; these include infections such as line infections, wound infections, pneumonia, and urinary tract infection (UTI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-operative Complications</measure>
    <time_frame>~3 months</time_frame>
    <description>Any complications during the admission after start of study; these include anything including infections, necrotizing enterocolitis (NEC), small bowel obstruction (SBO), and Total Parenteral Nutrition (TPN)-induced cholestasis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Gastroschisis</condition>
  <arm_group>
    <arm_group_label>Glycerin Suppository Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-suppository Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerin Suppository</intervention_name>
    <description>Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
    <arm_group_label>Glycerin Suppository Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of uncomplicated gastroschisis&#xD;
&#xD;
          -  Gestational age &gt;33 weeks at time of delivery&#xD;
&#xD;
          -  Weight &gt;1900g at time of delivery&#xD;
&#xD;
          -  Transfer of patient to Riley Hospital for Children prior to any abdominal surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological Congenital malformations and/or those known to impair intestinal motility&#xD;
&#xD;
          -  Additional congenital gastrointestinal abnormalities requiring surgical intervention&#xD;
&#xD;
          -  Congenital Cyanotic heart disease&#xD;
&#xD;
          -  Surgical Closure of abdominal wall defect with prosthetic material (e.g. prosthetic or&#xD;
             bio-prosthetic mesh)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Ladd, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Program Director, Department of General Surgery, Divison of Pediatric Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <results_first_submitted>July 20, 2021</results_first_submitted>
  <results_first_submitted_qc>September 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Alan P. Ladd</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroschisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03355326/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03355326/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glycerin Suppository Group</title>
          <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
        </group>
        <group group_id="P2">
          <title>Non-suppository Group</title>
          <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glycerin Suppository Group</title>
          <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
        </group>
        <group group_id="B2">
          <title>Non-suppository Group</title>
          <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="2.75" upper_limit="6.75"/>
                    <measurement group_id="B2" value="4.5" lower_limit="4.0" upper_limit="5.25"/>
                    <measurement group_id="B3" value="5.0" lower_limit="4.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.39" lower_limit="2.17" upper_limit="2.73"/>
                    <measurement group_id="B2" value="2.53" lower_limit="2.37" upper_limit="2.79"/>
                    <measurement group_id="B3" value="2.49" lower_limit="2.23" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prenatal gastroschisis diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Size of Silo</title>
          <population>one patient did not have silo placed</population>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="4.0" upper_limit="5.5"/>
                    <measurement group_id="B2" value="4.0" lower_limit="4.0" upper_limit="4.38"/>
                    <measurement group_id="B3" value="4.0" lower_limit="4.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Full Enteral Feeds</title>
        <description>time from study start time to goal full feeds by enteral route (per oral (PO), orogastric (OG), gastrostomy tube (gtube)).</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerin Suppository Group</title>
            <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
          <group group_id="O2">
            <title>Non-suppository Group</title>
            <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Full Enteral Feeds</title>
          <description>time from study start time to goal full feeds by enteral route (per oral (PO), orogastric (OG), gastrostomy tube (gtube)).</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="14.25" upper_limit="22.75"/>
                    <measurement group_id="O2" value="17.0" lower_limit="15.25" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.971</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Bowel Movement</title>
        <description>time from study start time after closure to first bowel movement</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerin Suppository Group</title>
            <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
          <group group_id="O2">
            <title>Non-suppository Group</title>
            <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Bowel Movement</title>
          <description>time from study start time after closure to first bowel movement</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.0" upper_limit="3.75"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.75" upper_limit="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.900</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>time from admission (birth) to hospital discharge</description>
        <time_frame>~3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerin Suppository Group</title>
            <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
          <group group_id="O2">
            <title>Non-suppository Group</title>
            <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>time from admission (birth) to hospital discharge</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="22.5" upper_limit="35.25"/>
                    <measurement group_id="O2" value="23.5" lower_limit="21.75" upper_limit="27.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.648</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Total Parenteral Nutrition (TPN)</title>
        <description>total time that patient required Total Parenteral Nutrition (TPN) feeds</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerin Suppository Group</title>
            <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
          <group group_id="O2">
            <title>Non-suppository Group</title>
            <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Total Parenteral Nutrition (TPN)</title>
          <description>total time that patient required Total Parenteral Nutrition (TPN) feeds</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="16.5" upper_limit="23.75"/>
                    <measurement group_id="O2" value="20.5" lower_limit="17.25" upper_limit="24.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.967</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sequela of Long Term Total Parenteral Nutrition (TPN) Administration</title>
        <description>Any complications related to TPN administration, including TPN-induced cholestasis and hyperbilirubinemia</description>
        <time_frame>~3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerin Suppository Group</title>
            <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
          <group group_id="O2">
            <title>Non-suppository Group</title>
            <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sequela of Long Term Total Parenteral Nutrition (TPN) Administration</title>
          <description>Any complications related to TPN administration, including TPN-induced cholestasis and hyperbilirubinemia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infectious Complications</title>
        <description>Any complications related to infections during the admission after start of study; these include infections such as line infections, wound infections, pneumonia, and urinary tract infection (UTI)</description>
        <time_frame>~3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerin Suppository Group</title>
            <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
          <group group_id="O2">
            <title>Non-suppository Group</title>
            <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infectious Complications</title>
          <description>Any complications related to infections during the admission after start of study; these include infections such as line infections, wound infections, pneumonia, and urinary tract infection (UTI)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-operative Complications</title>
        <description>Any complications during the admission after start of study; these include anything including infections, necrotizing enterocolitis (NEC), small bowel obstruction (SBO), and Total Parenteral Nutrition (TPN)-induced cholestasis.</description>
        <time_frame>~3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerin Suppository Group</title>
            <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
          <group group_id="O2">
            <title>Non-suppository Group</title>
            <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-operative Complications</title>
          <description>Any complications during the admission after start of study; these include anything including infections, necrotizing enterocolitis (NEC), small bowel obstruction (SBO), and Total Parenteral Nutrition (TPN)-induced cholestasis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, an average [or up to] 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Glycerin Suppository Group</title>
          <description>Glycerin Suppository: Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.</description>
        </group>
        <group group_id="E2">
          <title>Non-suppository Group</title>
          <description>Non-Suppository: No suppository is given beginning after conditions described are met and continued until discontinue conditions are met.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postop infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alan Ladd, Principle Investigator</name_or_title>
      <organization>Indiana University, School of Medicine</organization>
      <phone>317-274-4606</phone>
      <email>aladd@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

